

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1. (Currently Amended) A method for identifying a leukemia or for identifying the propensity of developing a leukemia of T cell, B cell, or myeloid lineage in a human subject, said method comprising:

contacting a biological sample comprising leukocytes from the human subject with an array of immunoglobulin molecules immobilized to a solid support, wherein the array comprises ~~7~~ from 20 to about 1000 immunoglobulin regions, wherein each region comprises the immunoglobulin molecules that are specific for a distinct cell surface marker ~~antigen~~ antigen, wherein binding of the immunoglobulin molecules to the distinct cell surface marker antigens provides a pattern of expression on the leukocytes that distinguishes leukemias of T cell, B cell, or myeloid lineage. and wherein the cell surface marker antigens comprise at least seven cell surface marker antigens ~~are selected from the list in Table 4, and wherein the such that the pattern of expression of the cell surface antigens on the leukocytes cell surface marker antigens distinguish~~ distinguishes leukemias of T cell, B cell, or myeloid lineage; and

determining the relative scale of the pattern of expression with which cell surface marker antigens have bound to which immobilized immunoglobulin molecules to establish a differential pattern of density of binding that identifies a leukemia that is of T cell, B cell, or myeloid lineage.

2. (Previously Presented) The method of claim 1, wherein the immunoglobulin molecules are monoclonal antibodies.

3. – 17. (Canceled)

18. (Previously Presented) The method of claim 1 wherein the immunoglobulin molecules are polyclonal antibodies.

19. (Previously Presented) The method of claim 1 wherein the biological sample is selected from the list consisting of tissue fluid, blood, cerebrospinal fluid, lymphatic fluid, seminal fluid, bone marrow aspirate and mucus.

20. (Previously Presented) The method of claim 19 wherein the biological sample is blood.

21. (Previously Presented) The method of claim 1, wherein the immunoglobulin molecules are antigen binding fragments of immunoglobulin molecules.

22. – 23. (Canceled)

24. (New) The method of claim 1 wherein the array of immunoglobulins comprises at least 40 discrete regions wherein each region comprises immunoglobulin molecules that are specific for a distinct cell surface marker antigen.

25. (New) The method of claim 1 wherein the array of immunoglobulins comprises at least 60 discrete regions wherein each region comprises immunoglobulin molecules that are specific for a distinct cell surface marker antigen.

26. (New) The method of claim 1 further comprising microscopic analysis of cellular morphology of the leukocytes.

27. (New) The method of claim 1 further comprising histochemical, biochemical, or immunological analysis of the leukocytes.